Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Provided By GlobeNewswire
Last update: Feb 13, 2025
AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentation will feature results from the IND-enabling toxicology studies of SL-325, a first-in-class DR3 blocking antibody, in non-human primates.
Read more at globenewswire.com0.7851
+0.01 (+1.53%)
Find more stocks in the Stock Screener
STTK Latest News and Analysis
13 days ago - ChartmillWhich stocks are moving on Tuesday?Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
13 days ago - ChartmillWondering what's happening in today's pre-market session?As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
14 days ago - ChartmillWondering what's happening in today's after-hours session?The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
14 days ago - ChartmillWhich stocks are moving on Monday?Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
